Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atopiclair is a non-steroidal topical emollient formulated as a cream or lotion for the management of atopic dermatitis (eczema), allergic contact dermatitis, and other dry or sensitive skin conditions. It is clinically proven to relieve symptoms such as itching, burning, and pain associated with these dermatological disorders. The product contains glycyrrhetinic acid (derived from licorice root) with anti-inflammatory and anti-itch properties; hyaluronic acid for moisturizing; shea butter and other lipids to restore the skin barrier; along with additional soothing ingredients like bisabolol and allantoin. Atopiclair works by hydrating the skin and restoring its natural barrier function without using steroids or parabens. It can be used during both flare-ups and remission phases of eczema in adults and children over 6 months old[1][3][5][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atopiclair.